In a previous study (Hajnická et al., Acta virol. 38, 55-57 (1994)), we described synthesis of a 23 K protein in high amounts in the PLC/PRF/5 human hepatoma cell line after stimulation with sera of patients suffering from liver cirrhosis. In this study we identified this protein as manganense superoxide dismutase (Mn-SOD). When PLC/PRF/5 cells stimulated by various cytokines (interleukin-1 alpha (IL-1 alpha), IL-1 beta, tumor necrosis factor-alpha (TNF-alpha), TNF-beta, IL-6, tumor growth factor-alpha (TGF-alpha), TGF-beta, and interferon-gamma (IFN-gamma) were compared, the most effective was IL-1, followed by TNF-alpha and IL-6. Other cytokines had no effect on the stimulation of Mn-SOD. IL-1 alpha was selected for stimulation of Mn-SOD production in four human hepatoma cell lines (PLC/PRF/5, Hep-3B, Hep-G2 and Sk-Hep 1). Maximum Mn-SOD production occurred in PLC/PRF/5 cells. In other cell lines, Mn-SOD production was lower, reaching 35.7% and 31.5% in Hep-3B and Sk-Hep-1 cells, respectively, while it was only 4.3% in Hep-G2 cells.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparison of Patient-Generated Subjective Global Assessment (PG-SGA) and Mini Nutritional Assessment (MNA) for nutritional assessment in hepatocellular carcinoma patients.
Support Care Cancer
January 2025
Department of Medicine, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand.
Background: Malnutrition affects the prognosis and response to treatment in cancer patients. There is no gold standard for nutritional assessment in patients with hepatocellular carcinoma (HCC). This study aimed to compare Patient-Generated Subjective Global Assessment (PG-SGA) and Mini Nutritional Assessment (MNA) in predicting mortality in HCC patients.
View Article and Find Full Text PDFContrast-enhanced US of High-Risk Indeterminate Focal Liver Observations Categorized as LR-4 or LR-M at CT/MRI.
Radiology
January 2025
From the Department of Radiology, Thomas Jefferson University Hospital, 132 S 10th St, 763G Main Bldg, Philadelphia, PA 19107 (A.L., C.K.Y.E., T.S.X., S.K.R., C.E.W., K.B., J.R.E., F.F.); Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (F.P.); Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy (F.P.); University of California San Diego, San Diego, Calif (Y.K.); University of Calgary, Calgary, Canada (A.M.K., S.R.W.); Einstein Medical Center, Philadelphia, Pa (S.K.R.); Vanderbilt University, Nashville, Tenn (V.P.); Stanford University, Stanford, Calif (A.K.); UT Southwestern Medical Center, Dallas, Tex (D.T.F.); Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, Switzerland (A.B., I.P.R.); Department of Imaging Sciences, School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom (P.S.S.); and Department of Radiology, King's College Hospital, London, United Kingdom (P.S.S.).
Background Indeterminate focal liver observations in patients at risk for hepatocellular carcinoma (HCC) may require invasive biopsy or follow-up, which could lead to delays in definitive categorization and to postponement of treatment. Purpose To examine clinical effect of contrast-enhanced US (CEUS) in participants with high-risk indeterminate liver observations categorized as Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) or LI-RADS category LR-M (probably or definitely malignant but not HCC specific) at CT or MRI. Materials and Methods This was a secondary analysis of a prospective international multicenter validation study for CEUS LI-RADS (January 2018 to August 2021).
View Article and Find Full Text PDFSingle-cell mitophagy patterns within the tumor microenvironment modulate intercellular communication, impacting the progression and prognosis of hepatocellular carcinoma.
Front Immunol
January 2025
Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing, China.
Background: Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system with a high incidence that seriously threatens patients' lives and health. However, with the rise and application of new treatments, such as immunotherapy, there are still some restrictions in the treatment and diagnosis of HCC, and the therapeutic effects on patients are not ideal.
Methods: Two single-cell RNA sequencing (scRNA-seq) datasets from HCC patients, encompassing 25,189 cells, were analyzed in the study.
Macrotrabecular-Massive Hepatocellular Carcinoma: A Case Report.
Cureus
December 2024
Department of Clinical Immunology and Allergology, Iuliu Hatieganu University of Medicine and Pharmacy of Cluj, Cluj-Napoca, ROU.
Macrotrabecular-massive hepatocellular carcinoma (MTM-HCC) is a rare and aggressive molecular subtype of hepatocellular carcinoma (HCC) associated with a poor prognosis. Unlike typical HCC, which commonly arises in the context of cirrhosis, MTM-HCC can develop in non-cirrhotic livers, presenting unique diagnostic and therapeutic challenges. This case report describes a 35-year-old male who presented with persistent epigastric pain, fatigue, and loss of appetite.
View Article and Find Full Text PDFRisk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis.
Ann Med
December 2025
Department of Hepatobiliary and Pancreatic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China.
Background: Numerous meta-analyses have identified various risk factors for hepatocellular carcinoma (HCC), prompting a comprehensive study to synthesize evidence quality and strength.
Methods: This umbrella review of meta-analyses was conducted throughout PubMed, EMBASE, Web of Science, and Cochrane Database of Systematic Reviews. Evidence strength was evaluated according to the evidence categories criteria.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!